

RESEARCH

Open Access

miR-449 inhibits cell proliferation and is down-regulated in gastric cancer

Tony Bou Kheir^{1†}, Ewa Futoma-Kazmierczak^{2†}, Anders Jacobsen³, Anders Krogh³, Linda Bardram⁴, Christoffer Hother⁵, Kirsten Grønbaek⁵, Birgitte Federspiel⁶, Anders H Lund^{1*}, Lennart Friis-Hansen^{2*}

Abstract

Background: Gastric cancer is the fourth most common cancer in the world and the second most prevalent cause of cancer related death. The development of gastric cancer is mainly associated with *H. Pylori* infection leading to a focus in pathology studies on bacterial and environmental factors, and to a lesser extent on the mechanistic development of the tumour. MicroRNAs are small non-coding RNA molecules involved in post-transcriptional gene regulation. They are found to regulate genes involved in diverse biological functions and alterations in microRNA expression have been linked to the pathogenesis of many malignancies. The current study is focused on identifying microRNAs involved in gastric carcinogenesis and to explore their mechanistic relevance by characterizing their targets.

Results: Invitrogen NCode miRNA microarrays identified miR-449 to be decreased in 1-year-old *Gastrin* KO mice and in *H. Pylori* infected gastric tissues compared to tissues from wild type animals. Growth rate of gastric cell lines over-expressing miR-449 was inhibited by 60% compared to controls. FACS cell cycle analysis of miR-449 over-expressing cells showed a significant increase in the sub-G₁ fraction indicative of apoptosis. β-Gal assays indicated a senescent phenotype of gastric cell lines over-expressing miR-449. Affymetrix 133v2 arrays identified *GMNN*, *MET*, *CCNE2*, *SIRT1* and *CDK6* as miR-449 targets. Luciferase assays were used to confirm *GMNN*, *MET*, *CCNE2* and *SIRT1* as direct targets. We also show that miR-449 over-expression activated p53 and its downstream target p21 as well as the apoptosis markers cleaved CASP3 and PARP. Importantly, qPCR analyses showed a loss of miR-449 expression in human clinical gastric tumours compared to normal tissues.

Conclusions: In this study, we document a diminished expression of miR-449 in *Gastrin* KO mice and further confirmed its loss in human gastric tumours. We investigated the function of miR-449 by identifying its direct targets. Furthermore we show that miR-449 induces senescence and apoptosis by activating the p53 pathway.

Background

Gastric cancer is among the five most common cancers in the world and the second most prevalent cause of cancer-related deaths [1]. It is mainly, but not exclusively, caused by *H. Pylori* infection [2] as not all of *H. Pylori* infected persons develop tumours [3]. Other factors involved in the development of gastric cancer include the degree and type of the inflammatory response [2] as well as the levels of the *Gastrin*

hormone [4,5]. Several studies have shown that both hypergastrinemia [6,7] and the lack of *Gastrin* [5] contribute to the pathogenesis of gastric cancer. Achlorhydria is a common feature of mouse models prone to developing metaplasia and cancer [6,8,9]. *Gastrin* knock-out mice are achlorhydric [10], favouring a bacterial gastric overgrowth [11,12], and chronic bacterial gastric infections lead to gastric metaplasia which may progress into gastric cancer [6,12].

Since their discovery microRNAs, have been found implicated in a very wide range of normal and pathological processes [13]. MicroRNAs exert their regulatory functions posttranscriptionally by binding to partly complementary sequence motifs predominantly in the 3' UTR of target mRNAs resulting in mRNA destabilization

* Correspondence: anders.lund@bric.ku.dk; lfh@rh.regionh.dk

† Contributed equally

¹BRIC - Biotech Research & Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark

²Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Full list of author information is available at the end of the article

and translational repression [14]. From a biological point of view, microRNAs are challenging objects to study as they regulate cohorts of target genes, which are not readily identified. From a therapeutic point of view, microRNAs are highly interesting as several studies have demonstrated the power of microRNAs as biomarkers and initial preclinical studies have established that microRNAs may be therapeutically targeted in vivo [15].

Profiling studies have evidenced microRNA deregulation in a broad spectrum of diseases including all major cancers [16]. MicroRNAs likely affect tumourigenic processes at two levels. Firstly, several studies have established pro-oncogenic or tumour-suppressive roles of individual microRNAs firmly linking these to cancer etiology as exemplified by miR-155, miR-10b and miR-21 [17-19]. Secondly, the microRNA regulatory system per se appears to have tumour suppressive functions as genetic ablation of key microRNA biogenesis factors, such as Dicer, strongly increase cancer susceptibility [20] and loss of function mutations have been identified in important microRNAs processing factors in human tumours [21-23].

In this study, we address the importance of microRNAs in gastric cancer taking advantage of the *Gastrin* knockout mouse model and *H. pylori* infection of wild type mice. We identify miR-449 as significantly down-regulated or lost in mouse models of gastric cancer as well as in primary human gastric tumours. Identification of mRNA targets reveals that this microRNA likely exerts tumour suppressive functions through the concerted regulation of a cohort of cancer-associated cell-cycle regulators including MET, GMNN, CCNE2, SIRT1, and HDAC1.

Methods

Mice

Three different age groups (12-16 weeks, 1 year or 1½ years) of wild type (wt) or *Gastrin* knockout (KO) mice were used. All mice were on a mixed 129/SvJ, C57BL/6J background, backcrossed at least four times to C57BL/6J [12]. The mice were kept under specific pathogen-free conditions and monitored according to the Federation of European Laboratory Animal Science Associations recommendation [24] with 12 h light, 12 h dark cycles.

H. pylori infection

C57BL6/J mice (n = 10) were inoculated with a non-mouse-adapted clone of *H. Pylori* strain 67:21, originally isolated from an antral biopsy obtained from a Swedish female with gastric ulcer. The strain is VacA⁺ and contains the entire Cag pathogenicity island (PAI) with genetic stability in the Cag PAI [25]. The mice were inoculated every second day (three times) during a 5-day period. DNA was extracted and analyzed for the

presence of helicobacter species using a semi-nested polymerase chain reaction-denaturing gradient gel electrophoresis assay, specific for the genus helicobacter, as described previously [26]. A matched group of uninfected C57BL6/J mice were used as controls.

The stomachs of all mice were dissected into fundus and antrum prior to RNA extraction. All animal experiments were approved by the Danish Animal Welfare Committee (2005/562-40) and the Danish Forest and Nature Agency (20010077355/6).

Mice antrum sections

Mice were sacrificed by cervical dislocation. The antrum was removed, washed gently in ice-cold PBS, frozen in liquid nitrogen and stored at -80°C until RNA extraction.

Clinical samples analyses

Biopsies from gastric cancer and the adjacent normal tissues were obtained from patients undergoing surgery for gastric cancer at the Department of Gastrointestinal Surgery, Rigshospitalet. The inclusion took place in July to December 2008 and all patients provided signed, informed consent (Ethical committee approval H-B-2008-049) and Danish Data Protection Agency (2008-41-2138). The biopsies were placed in RNAlater (Ambion) in the operating room and subsequently frozen at -80°C until RNA extraction.

RNA extraction and qPCR analyses

RNA was extracted using TRIzol (Invitrogen) according to manufacturer. miRNA expression profile was assessed using Taqman miRNA assays (Applied biosystems) for hsa/mmu-miR-449a and b, hsa/mmu-miR-34a, b and c and rnu44 or hsa/mmu-miR-191. Primer sequences for Affymetrix targets validation are listed in additional file 1, table S1.

Cell culture

SNU638 and MKN74 were grown in RPMI-1640 (Gibco) with 10% FBS (Hyclone), 100U/ml penicillin and 100 µg/ml streptomycin (Invitrogen) and incubated at 37°C in 5% CO₂. HCT116 cells (wt and p53^{-/-}) were grown in McCoy's 5A (Gibco) with 10% FBS (Hyclone), and 100U/ml penicillin and 100 µg/ml streptomycin (Invitrogen) and incubated at 37°C in 5% CO₂. HEK293 and MEF cells (wt and p53^{-/-}) were grown in DMEM (Gibco) with 10%FBS (Hyclone), 100U/ml penicillin and 100 µg/ml streptomycin (Invitrogen) and incubated at 37°C with 5% CO₂.

miRNA precursors and siRNA

miRNA precursors were purchased from Ambion, hsa-miR-449a (PM11521), hsa-miR-449b (PM11127) and hsa-miR-34a (PM11030).

Cell growth analyses

SNU638 cells were seeded in 24-well plates and transfected the following day with 50nM miRNA duplex or siRNA using Lipofectamine 2000 (Invitrogen). Cells were fixed at indicated time points in 4% paraformaldehyde, stained in a 0.1% crystal violet solution, and resuspended in 10% acetic acid. Sample absorbance was measured at 620 nm.

Cell cycle FACS analyses

SNU638 and MKN74 cells were seeded at 2×10^6 cells per 10cm plate and transfected with 50nM miRNA duplex (Ambion) using Lipofectamine 2000 (Invitrogen). Cells were harvested 48 and 72 hours post-transfection, stained for DNA content using propidium iodide (PI) and analyzed on a FACS Calibur flow cytometer (Becton-Dickinson). Briefly, cells were harvested by trypsinization and washed once with PBS before fixing overnight in 70% EtOH. To stain the DNA, cells were pelleted, re-suspended in 100 μ l EtOH and stained for 1 hour with 300 μ l PI solution (0.05mg/ml PI, 20 μ g/ml RNase A in 0.1%BSA).

Senescence analyses

SNU638 cells were seeded at 400.000 cells per 6-well-plate and transfected with 50nM miRNA duplex (Ambion) using Lipofectamine 2000 (Invitrogen). Four days post-transfection, cells were washed in PBS and fixed for 5 minutes at room temperature in 2% formaldehyde/0.2% glutaraldehyde. Cells were washed twice in PBS pH6.0 before being stained with fresh senescence associated β -Gal stain solution (1mg/ml 5-bromo-4-chloro-3-indolyl- β D-galactoside (X-Gal), 0.12mM $K_3Fe[CN]_6$, 0.12mM $K_4Fe[CN]_6$, 1mM $MgCl_2$ in PBS pH6.0) overnight at 37°C without CO_2 supply. Cells were washed once in PBS (pH6.0) and observed under the microscope.

Antibodies and western blot analyses

SNU638 were seeded at 2×10^6 cells per 10 cm plate, transfected twice on two successive days with 50nM miRNA duplexes using Lipofectamine 2000 according to manufacturer (Invitrogen). Cells were harvested by trypsinization, washed once with PBS and lysed in RIPA buffer (150mM NaCl, 0.5% Sodium Deoxycholate, 0.1% SDS, 1% Igepal, 50mM Tris-HCl pH8, 2mM EDTA) supplemented with 1mM DTT, 1mM Pefabloc, 1mM NaV3, 10mM NaF and 1X complete mini protease inhibitor cocktail tablets. 25 μ g of protein/lane were resolved on 4-20% NuPAGE Bis-Tris gels (Invitrogen) and transferred to a nitrocellulose membrane. Primary antibodies used were MET (Cell Signal 4560), MYC (Cell Signal 9402), GMNN (Santa Cruz Sc-53923), VCL (Sigma V9131), TP53 (Santa Cruz Sc-126), CDKN1A

(Santa Cruz Sc-6246), CDK6 (Santa Cruz Sc-177), HDAC1 (Santa Cruz Sc-7872), CCNE2 (Cell Signal 4132), TUBB (Abcam ab11304), PARP (Cell Signal 9542) and Cleaved CASP3 (Cell Signal 9661).

Microarray analyses

Small RNAs (< 200 nt) were isolated with Invitrogen PureLink miRNA Isolation Kit from fundic and antral tissue from 1) *Gastrin* KO mice and age and sex matched C57BL6/J control mice, and 2) C57BL6/J mice infected with *H. Pylori* and uninfected age and sex matched C57BL6/J control mice, (n = 4 for each group). The quality of isolated small RNAs was determined using the Small RNA Assay on an Agilent Bioanalyzer. 500ng of small RNA was labelled with Genisphere FlashTag Kit and hybridized to Invitrogen NCode Multi-Species miRNA Microarray V2 in a Maui hybridization station. Processed slides were scanned in an Agilent DNA microarray scanner. Resulting images was analyzed and ratio of median normalized using GenePix Pro 6.0. Four biological replicates were used for each comparison. Samples were hybridized to four arrays in a dual colour dye swap microarray experimental design. BRB ArrayTools were used for fold change and statistical calculations. Selected miRNA data from the array analysis were validated using TaqMan real-time PCR miRNA assays. Data will be deposited at ArrayExpress upon acceptance.

mRNA arrays

SNU638 were transfected with 50 nM of miR-34a or miR-449b duplexes with siGLO siRNA used as negative control. Total RNA was extracted 24 hours post-transfection using TRIzol reagent. Affymetrix microarray analysis (HG-U133 Plus 2.0 human) was performed at the Microarray Center, Rigshospitalet, Copenhagen University Hospital. Experiments were run in either triplicates or quadruplicates. Data will be deposited at ArrayExpress upon acceptance.

Vectors construction and reporter assays

The 3'UTRs of *HDAC1*, *SIRT1*, *MET*, *GMNN* and *CCNE2* holding miR-449 binding sites were cloned downstream of the luciferase reporter in pMIR-REPORT vector system (Ambion). Quickchange site-directed mutagenesis kit (Stratagene) was used to induce two point mutations into the seed region. Mutagenesis primers sequences are listed in Additional file 1, table S1.

HEK293 cells were seeded in 96 well plates and transfected with 20nM miRNA precursor or scrambled siRNA control, 20-50ng of luciferase vector (pMIR-report) and 5ng of renilla vector (pRL-TK) using lipofectamine 2000 (Invitrogen). Cells were harvested 24 hours post transfection and luciferase activity was measured using Dual-Glo luciferase assay (Promega).

Microarray analysis

Microarray expression data was processed using the 'affy' package in BioConductor [27]. Probe set intensities were summarized and quantile normalized using the BioConductor RMA and VSN packages. Differential expression was determined per probeset using a t-test. Probe sets were mapped to Ensembl transcripts (version 49) using mappings provided at BioMart. Probesets that mapped to two different Ensembl genes were discarded.

Evaluating global down-regulation of microRNA target genes

The 3'UTRs, 5'UTRs and coding sequences of the transcripts were scanned for matching 6mer, 7mer and 8mer miRNA seed sites (complementary to position 2-7, 2-8, and 2-9 of the miRNA). Global analysis of miRNA target down-regulation was evaluated using the longest 3'UTR sequence per gene to avoid bias introduced by genes with many transcript isoforms. We discarded transcripts with 3'UTR sequences shorter than 50 nt. To globally evaluate if miRNA target genes were down-regulated after miRNA transfection, we tested the null hypothesis that the expression change distribution of miRNA targets (having a 7mer target site) was equal to the distribution of all expressed genes without predicted target sites using the non-parametric Wilcoxon rank-sum test. A similar approach was used to evaluate down-regulation of genes with miRNA target sites in coding regions and 5'UTRs of mRNAs.

Exhaustive statistical assessment of words correlated with down-regulation

We used a previously published non-parametric rank-based statistic to exhaustively assess the correlation of word occurrences in 3'UTRs and the change in gene expression after miRNA transfection [28,29]. Genes were sorted by expression change induced by transfection of miR-34a or miR-449b, and the correlation with down-regulation was tested for all words of length 5-7 (N = 21 504).

Statistical tests

Students t-test with Welch's correction.

Results

miR-449b is down regulated in the antrum of both *Gastrin* KO mice and *H. pylori* infected mice

Gastrin knockout mice are achlorhydric with a tendency for developing antral hyperplasia and gastric adenomas over time (figure 1) [6,12]. In order to identify microRNAs deregulated during the development of gastric cancer, we examined miRNAs expression profiles in gastric neoplasias from *Gastrin* knockout mice using miRNA microarrays. As shown in table 1, 20 microRNAs were

significantly deregulated in the knockout mice compared to wild type littermate controls, with three miRNAs differing more than two fold, miR-7 being up-regulated and miR-709 and miR-449b being down-regulated in the antrum of *Gastrin* knockout mice compared to wild types. To further confirm miR-449 deregulation during gastric cancer development, we examined its expression in wild type mouse antrum tissues infected with *H. Pylori*. Interestingly, miRNA arrays demonstrated a specific down-regulation of miR-449b in *H. Pylori* infected mice (table 2 and Additional file 1, figure S1).

miR-449 inhibits cell cycle progression and induces senescence

Having demonstrated down-regulation of miR-449 expression in gastric cancers we wanted to examine the effect of re-expressing miR-449 in gastric cancer cell lines. Interestingly no noticeable expression of the miR-449 family was detected across a panel of gastric cell lines including SNU638, SNU5, SNU216, SNU601 and MKN74 sustaining the notion of miR-449 having tumour-suppressive functions (data not shown). The miR-449 family consists of miR-449a and b in humans and miR-449a, b and c in mice. Interestingly, they share the same seed sequence as the miR-34 family and are hence expected to regulate overlapping cohorts of target genes (figure 2a). To assess the function of miR-449 in gastric cell lines we re-introduced miR-449b in SNU638 and MKN74 cells. Compared to negative control microRNAs, re-introduction of miR-449b strongly affected the proliferation of SNU638 cells (figure 2b) and visual inspection of the cells indicated induction of apoptosis and cellular senescence (figure 2c, and Additional file 1, figure S2). Flow cytometric analysis of propidium iodide-stained cells transfected with miR-449b showed a G₁ accumulation 48 hours after transfection, followed at 72 hours post transfection by an accumulation of cells in the sub G₁ fraction suggestive of cell death (figure 2d). The induction of cellular senescence was confirmed by acidic beta gal staining using miR-34a as a positive control microRNA (figure 2e). To rule out cell line-specific effects, the functional consequences of miR-449 re-introduction in terms of cell cycle arrest were verified in MKN74 cells (Additional file 1, figure S3). Thus, re-introduction of miR-449 negatively affects proliferation of gastric cancer cell lines concomitant with the induction of senescence and apoptosis in concordance with miR-449 having tumour suppressive functions.

The joint seed sequence of miR-449b and miR-34a induce highly correlated expression changes

To characterize the transcripts controlled by miR-449 and to see if miR-449 regulates different transcripts than miR-34a, SNU638 cells expression profiles were examined




Figure 1 Old *Gastrin* knockout mice develop gastric adenomas. Antrum sections isolated from 12-16 weeks old mice (left panel), 12 to 18 months old mice (middle panel) and older than 18 months mice (right panel), from wild type (upper panel) and *Gastrin* knockout mice (lower panel). Sections show adenoma development in antrum tissues in the *Gastrin* knockouts compared to the wild types.

24 hours post transfection of miR-449b or miR-34a and differentially expressed transcripts identified. We found that mRNAs with predicted miRNA target sites (7 mer seed site) in the 3'UTR were significantly down-regulated compared to mRNAs without predicted target sites after transfection of miR-449b ($p < 1.2e-70$, two-tailed Wilcoxon rank-sum test), (Additional file 1, figure S4a). mRNAs having predicted miRNA seed target sites in

coding regions were also found to be significantly down-regulated ($p < 9.9e-25$), while mRNAs with sites in 5'UTRs were only marginally down-regulated ($p < 5.3e-2$). The expression changes induced by transfection of mature miR-449b and miR-34a were highly correlated despite divergence of the mature sequences outside the seed region (Pearson's correlation coefficient $R = 0.94$, $p = 0$), (Additional file 1, figure S4b). We exhaustively evaluated all oligonucleotides (words) of length 5-7 for correlation with down-regulation after miR-449b and miR-34a transfection (see methods). Consistent with many previous studies, this analysis revealed the shared miR-34a/449b seed site as the 3'UTR word most correlated with down-regulation in the two experiments (Additional file 1, figure S4c).

Table 1 miRNAs deregulated in *Gastrin* knockout mice

miRNA Name	Log2-fold	p-value	miRNA Name	Log2-fold	p-value
mmu-miR-709	-1.73	7.0E-06	mmu-miR-422b	0.44	4.6E-02
mmu-miR-449b	-1.37	1.6E-03	mmu-miR-199a*	0.50	7.7E-03
mmu-miR-805	-1.01	7.5E-03	mmu-miR-25	0.51	1.6E-02
mmu-miR-706	-0.98	3.1E-03	mmu-miR-27b	0.56	5.1E-03
mmu-miR-467a	-0.88	2.8E-02	mmu-miR-182	0.56	1.8E-02
mmu-miR-696	-0.83	7.1E-03	mmu-miR-30a-3p	0.59	2.2E-02
mmu-miR-667	-0.66	2.3E-02	mmu-miR-10a	0.70	7.1E-03
mmu-miR-690	-0.28	1.7E-02	mmu-miR-152	0.70	2.3E-02
mmu-miR-18	0.29	3.7E-02	mmu-miR-1	0.77	7.1E-03
mmu-miR-143	0.34	2.3E-02	mmu-miR-7	1.06	4.9E-03

List of significantly deregulated miRNAs in gastric neoplasias from *Gastrin* Knockout mice compared to wild types.


miR-449 regulates numerous cell cycle controllers

The expression profiles were used to identify differentially expressed transcripts in cells transfected with miR-449b or controls (Additional file 1, table S2).

Table 2 miRNAs deregulated in *H. Pylori* infected tissues

miRNA name	Fold change	p-value
mmu-miR-122a	-3.247	0.000788
mmu-miR-449b	-0.879	0.045214


List of significantly deregulated miRNAs in wild type mice antrum infected with *H. Pylori* compared to non-infected antrum.



A pathway activation analysis based on the differentially regulated transcripts demonstrates that miR-449 mainly controls transcripts coding for proteins involved in cell damage responses, cell cycle control, inflammation and cancer pathways (figure 3a). Focusing on a set of putative target genes with well-established roles in tumourigenesis, we confirmed down-regulation by miR-449 of met proto oncogene (*MET*), cyclin dependent kinase 6 (*CDK6*), geminin (*GMNN*), myelocytomatosis viral oncogenes homolog (*MYC*), sirtuin 1 (*SIRT1*) and histone deacetylase 1 (*HDAC1*) at the transcript level (figure 3b). Western

blot analyses confirmed the ability of miR-449 to down-regulate *MET*, *GMNN*, *MYC*, *SIRT1*, cyclin E2 (*CCNE2*) and *HDAC1* at the protein level to an extent similar to that achieved by re-introduction of miR-34a (figure 3c). For a subset of target genes including *MET*, *GMNN*, *CCNE2*, *SIRT1* and *HDAC1*, we confirmed direct interaction of miR-449 with the target gene 3' UTR using luciferase assay (figure 3d).

Hence, miR-449 directly targets cell cycle regulator genes consistent with a tumour suppressor function and with the cell cycle arrest observed upon miR-449 re-introduction into cancer cell lines.



miR-449 induces p53 expression but is not regulated by p53

As miR-34a was previously found to function downstream of p53 [30-33], we analyzed if also miR-449a/b were linked to p53. This was furthermore spurred by the presence of a putative p53 binding site 10 kb upstream from human miR-449 (data not shown). We therefore induced p53 by DNA damage using UV or 5-fluorouracil (5FU) in four different systems, HCT116 and MEF wild type and p53 knockout cells (Additional file 1, figure S5a). However, no significant change in miR-449 expression was detected after p53 pathway

activation (Additional file 1, figure S5b). In conclusion, we found no evidence that miR-449 is a transcriptional target of p53. On the other hand, we found that miR-449a/b is able to induce activation of p53, activation of p53 response genes such as p21 and the induction of apoptosis as evidenced by cleavage of caspase 3 (CASP3) and poly (ADP-ribose) polymerase 1 (PARP) (figure 4). Towards understanding the mechanism by which miR-449 does this we examined the effect of miR-449 on SIRT1 and HDAC1. SIRT1 and HDAC1 are deacetylases which inhibit, among others, the activation of p53 and miR-34 has been shown to repress SIRT1 [34].




Figure 4 miR-449 activates the p53 pathway. Western blot analysis showing an increase of the p53 protein upon miR-449 and positive control miR-34a re-introduction into SNU638 cells compared to RNA scrambled control as well as an activation of the p53 downstream target p21 and apoptosis markers cleaved CASP3 and PARP. Vinculin (VCL) and tubulin beta (TUBB) were used as loading controls.

We validated the specific binding of miR-449 to SIRT1 and HDAC1 using 3'UTR luciferase assays (figure 3d).

Hence, we speculate that miR-449 induces apoptosis by inhibiting the histone deacetylase HDAC1 and SIRT1 leading to the p53 pathway activation thus the induction of apoptosis markers cleaved CASP3 and PARP.

miR-449 is down-regulated in human gastric cancers

To evaluate the importance of miR-449 in human malignancies we next examined the expression of miR-449 in 10 gastric cancer biopsies. Importantly, we found both miR-449a and b to be significantly down-regulated or absent in 8 out of 10 primary gastric cancers. Furthermore, the expression of miR-449a and b seem to be co-regulated (figure 5a). We did not find any correlation between the reduction in miR-449 expression and clinical characteristics of the cancer (figure 5b). Analyses of the genomic DNA from the tumours found no evidence for loss or hyper-methylation of the miR-449 loci using methylation-specific melting curve analysis (MS-MCA) indicating transcriptional down-regulation of expression (data not shown). Hence, in agreement with data from two mouse models of gastric inflammation and hyperplasia, the expression of miR-449 is down-regulated in human gastric cancers.


Discussion

Gastric cancer is a highly lethal malignancy with more than 21,500 new cases each year in the United States alone [35]. The disease is often detected late and the 5-year survival rate is consequently below 20% [36]. It is therefore important to understand the etiology and progression stages of the disease. The importance of the bacterial, environmental and host genetic risk factors in gastric carcinogenesis have been studied, however less is known about the molecular progression of the disease [37,38]. Among others, p53 pathway inactivation is reported in 30-60% of gastric cancers [39,40]

and recent studies suggest *H. pylori* direct modulation of the p53 gene or its downstream targets [41]. Another common alteration in gastric cancer is the perturbation of the cell cycle control via the over expression of Cyclin E1, which is associated with tumour aggressiveness and lymph node metastasis [42,43]. In contrast to our current understanding of the role of tumour suppressors and cell cycle factors, the knowledge about the post transcriptional changes affecting gene expression in gastric cancer is still incomplete.

Using the *Gastrin* knockout mouse model for gastric cancer [6,12], we identify 20 deregulated microRNAs of which 3 were more than 2-fold deregulated relative to their levels in normal gastric mucosa. As infection with *H. pylori* has been causally linked to gastric cancer [44,45], we next examined changes in microRNA expression levels following infection of wild type mice with *H. Pylori*. Interestingly, miR-449b was the only miRNA significantly deregulated in both mouse models. To establish a causal relationship between miR-449 deregulation and cancer-relevant parameters, such as cell cycle regulation, apoptosis and senescence, we over-expressed miR-449 in gastric cancer cell lines and observed a significant down-regulation of proliferation coupled with up-regulation of the acidic beta-gal senescence marker and induction of apoptosis. Importantly, analyses of primary gastric tumours from patients clearly documented a tumour-specific down-regulation of miR-449 also in humans. Previously, a number of studies have demonstrated deregulation of miRNA in gastric cancer [46-50] and the importance of the entire microRNA system has been documented in both gastric and colon cancer by the presence of cancer-specific mutations in the key RISC components *AGO2* and *TNRC6A* [51]. Furthermore, microRNAs are likely of important prognostic value in gastric cancer [52-54]. The present study represents the first report demonstrating

A



B

Patient #	1	2	3	4	5	6	7	8	9	10
Age	63	54	48	78	59	55	78	64	64	78
Sex	M	F	F	M	M	F	F	F	M	M
Localization	Gastro-esophageal junction	Gastro-esophageal junction	Gastro-esophageal junction	Gastro-esophageal junction	Gastro-esophageal junction	Gastro-esophageal junction	Antrum	Gastro-esophageal junction	Antrum	Gastro-esophageal junction
Laurén classification:	Diffuse	Intestinal/mucinous component	Diffuse	Intestinal/mucinous component	Intestinal/mucinous component	Intestinal	Intestinal	Intestinal	Diffuse/Signet ring cell	Intestinal
TNM 7	3	1b	3	3	3	3	3	1b	1a	3
Number of nodes	0	0	1	2	3	0	2	1	0	0
perineural invasion	Yes	No	No	Yes	Yes	Yes	Yes	No	No	No
intravascular growth	No	No	No	No	Yes	No	No	No	No	No
lymphocyte infiltration	small numbers	small numbers	numerous lymphocytes	moderate numbers	moderate numbers	moderate numbers	numerous lymphocytes	moderate numbers	numerous lymphocytes	moderate numbers
Degree of differentiation	Poorly differentiated	Moderately differentiated	Poorly differentiated	Moderately differentiated	Poorly differentiated	Moderately differentiated	Poorly differentiated	Poorly differentiated	Poorly differentiated	Well differentiated

Figure 5 miR-449 is down regulated in human gastric cancers. qPCR analysis (upper panel) showing down-regulation of miR-449 expression in 8 gastric cancer tissues compared to miR-449 expression in sample-matched controls (dotted line). U44 was used as endogenous control.

Table showing clinical information of patients (lower panel). "ns" not significant p value > 0.05, "*" significant 0.01 < p value < 0.05, "**" very significant 0.01 < p value < 0.001, "****" extremely significant p value < 0.001.

cancer-related down-regulation of miR-449 in both mouse models for gastric cancer and in primary human gastric tumours. Beside gastric cancer, the expression of miR-449 has also been found to be reduced in several cell lines [55] and in prostate cancer, where it was found to target *HDAC1* and induce growth arrest

following over-expression in prostate cancer cells [56]. In contrast, the expression of miR-449 has been reported to be increased in endometrioid adenocarcinoma [57] and melanoma in young adult patients [58]. The expression of miR-449 was also increased in skeletal muscle damage and regeneration [59].

To unveil molecular links between the loss of miR-449 and cancer progression or initiation we experimentally identified a number of direct mRNA targets using transcriptional profiling and extensive bioinformatics analysis. A series of the putative miR-449 targets were subsequently validated at endogenous level using western blotting and quantitative PCR and their direct regulation by miR-449 was established using heterologous reporter constructs and binding site-specific mutation studies. Prominent validated targets include *CDK6*, *MYC*, *CCNE2*, *MET* and *GMNN* and we furthermore validated the regulation of *HDAC1* and *SIRT1* also in gastric cancer cells. Hence, the cancer-specific loss or down-regulation of miR-449 in gastric cancer can likely be explained by the connection to key cell cycle regulators. During the search for miR-449 targets we also identified several growth factors (*AREG*, and *KITLG*) and growth factor receptors, such as *MET*, as targets. This suggests that deregulation of miR-449 not only leads to deregulated control of cell cycle proteins but also of growth factors and their receptors. Thus, another important property of miR-449 could be as a regulator of signals important for growth and migration/invasion.

Interestingly, miR-449 was recently shown to operate under the control of E2F1 [55,60]. This is highly interesting as it places miR-449 at a key node in a feed-back loop in which E2F1 activates the transcription of miR-449 that in turn targets *CDC25A* and *CDK6*. Reduced levels of *CDC25A* and *CDK6* decreases the phosphorylation of pRB and subsequently inhibits the release of E2F1 [55,60,61]. Hence, aside from the pro-oncogenic effects of up-regulation of *MYC*, *MET*, *CCNE2* and other direct targets, loss of miR-449 may result in increased E2F1 activity.

Many of the direct mRNA targets for miR-449 identified in this study are also targets of miR-34a and miR-449 and miR-34a belong to the same family of miRNAs as they share the same seed sequence. In accordance, miR-34a has been demonstrated to act as an important tumour-suppressor miRNA and reduced expression of miR-34a has been reported for neuroblastoma [62] and many other cancers [63]. In addition, the miR-34a gene is activated by p53 following DNA damage [30-33] and by ELK1 following over-expression of activated B-RAF [64].

In the present study, transcriptional profiling demonstrated that over-expression of miR-449 or miR-34a results in identical transcriptome changes. While this is underlining the dominant importance of the seed sequence in this type of over-expression study it also points to a limitation in the experimental approach. While miR-449 was clearly down-regulated or lost in the analyzed mouse tumour samples no clear tendency for loss or down-regulation of miR-34a was observed (data not shown). This indicates that these microRNAs

may have more deviant functions *in vivo* than suggested by the over-expression studies.

Finally, we examined the relationship between the p53 tumour suppressor and miR-449. As miR-34a has been firmly placed downstream from p53 [30-33] it was relevant to test if the same was the case for miR-449. In agreement with other studies [55,60], we did not observe a p53-dependent regulation of miR-449 in gastric cancer cells as well as in primary human and mouse fibroblasts. However, in agreement with previous findings for miR-34a, we find that miR-449 regulates the expression of p53 [31,32] as over-expression of miR-449 resulted in a potent up-regulation of p53 subsequently resulting in activation of p21 and induction of apoptosis markers, such as cleaved CASP3 and PARP as previously reported [60].

In summary, we have found that miR-449 may act as a tumour suppressor and is lost in gastric cancer. Its re-introduction into cancer cell lines leads to inhibition of cell proliferation by targeting different cell cycle regulators. We also found that re-introduction of miR-449 induces senescence and apoptosis. Hence, this study further underlines the importance of miRNAs in cancer and points to an important function for miR-449 in gastric cancer.

Additional material

Additional file 1: Figure S1 - miR-449 is down-regulated in *Gastrin* knock out mice compared to wild type. qPCR analysis of miR-449 expression in *Gastrin* knock out gastric tissues compared to relative expression in wild type gastric tissues, miR-449 is significantly down-regulated ($p = 0.04$) in *Gastrin* knock out tissues compared to wild types.

Figure S2 - miR-449 inhibits cell proliferation in human gastric cancer cell line MKN74. Visual inspection of human gastric cancer cell line (MKN74) upon miR-449 re-introduction (lower panel) showing a decrease in cell proliferation as well as a senescent like phenotype compared to scrambled RNA control (upper panel)

Figure S3 - miR-449 induces cell death in human gastric cancer cell line MKN74. FACS cell cycle analysis of MKN74 cell line upon miR-449 re-introduction (right histogram) showing an increase in the sub-G₁ fraction indicative of cell death compared to scrambled RNA control (left histogram), table showing percentage of cell accumulation in G₁ fraction 48 hours post miR-449 re-introduction followed by cell shift to the sub-G₁ fraction 72 hours post transfection compared to RNA scrambled control.

Figure S4 - miR-449b and miR-34a induce highly correlated expression changes. **A** - Chart showing significant down-regulation ($p < 1.2e-70$) of mRNAs with predicted miR-449 seed match in their 3'UTR (red line) compared to mRNAs lacking the seed match (black line). **B** - Chart showing high correlation of expression changes upon re-introduction of miR-449b or miR-34a into SNU638 cells with a Pearson's correlation coefficient of $r = 0.94$, $p = 0$. **C** - Word analysis showing shared miR-449b/34a seed site correlating with gene down-regulation.

Figure S5 - miR-449 expression is p53 independent. **A** -Western blot showing p53 induction in HCT116 wild types and p53 knockouts using 5FU. **B** - qPCR analyses of miR-449a and miR-449b post p53 induction. No significant change is observed.

Table S1 - primer sequences. Table S2 - list of genes deregulated upon miR-449 re-introduction. Affymetrix top down-regulated genes upon miR-449 re-introduction into SNU638 cells.

Acknowledgements

We thank Mikkel Klausen for technical assistance and Disa Tehler for her comments on the manuscript. Work in the authors' laboratories is supported

by The Danish National Research Foundation, The EC FP7 ONCOMIRS consortium (grant agreement number 201102). This publication reflects only authors' views. The commission is not liable for any use that may be made of the information herein), The Novo Nordisk Foundation, The Lundbeck Foundation, The Danish Cancer Society and the Danish National Advanced Technology Foundation.

Author details

¹BRIC - Biotech Research & Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark. ²Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ³Bioinformatics Centre, Institute of Molecular Biology University of Copenhagen, Copenhagen, Denmark. ⁴Department of Gastro-Intestinal, Rigshospitalet University of Copenhagen, Copenhagen, Denmark. ⁵Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ⁶Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Authors' contributions

TB performed cell cycle and senescence studies, targets validation and direct targets detection studies, p53 activation studies and miR-449 expression studies, conducted data analyses, contributed in designing the study and in writing the manuscript. EF performed the miRNA array, target identification experiments, growth assays and direct targets detection studies. miR-449 expression studies, conducted data analyses and contributed in writing the manuscript. AJ performed the bioinformatics on target identification, contributed in writing the manuscript. AK supervised the bioinformatics on target identification, contributed in writing the manuscript. LB collected the normal and tumour patient samples. CH performed the bio-informatical analysis of the miRNA arrays. KG performed the methylation assays. BF performed the pathological scoring of the pathological samples. AHL participated in designing the study and in writing the manuscript. LFH participated in designing the study and in writing the manuscript. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 7 September 2010 Accepted: 18 March 2011
Published: 18 March 2011

References

1. Smith MG, Hold GL, Tahara E, El-Omar EM: **Cellular and molecular aspects of gastric cancer.** *World J Gastroenterol* 2006, **12**:2979-2990.
2. Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P: **New aspects of Helicobacter pylori infection involvement in gastric oncogenesis.** *J Surg Res* 2008, **146**:149-158.
3. Polk DB, Peek RM Jr: **Helicobacter pylori: gastric cancer and beyond.** *Nat Rev Cancer* 2010, **10**:403-414.
4. Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG: **Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer.** *Gastroenterology* 2000, **118**:36-47.
5. Takaishi S, Tu S, Dubeykovskaya ZA, Whary MT, Muthupalani S, Rickman BH, Rogers AB, Lertkowitz N, Varro A, Fox JG, Wang TC: **Gastrin is an essential cofactor for helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice.** *Am J Pathol* 2009, **175**:365-375.
6. Zavros Y, Eaton KA, Kang W, Rathinavelu S, Katukuri V, Kao JY, Samuelson LC, Merchant JL: **Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma.** *Oncogene* 2005, **24**:2354-2366.
7. Friis-Hansen L: **Achlorhydria is associated with gastric microbial overgrowth and development of cancer: lessons learned from the gastrin knockout mouse.** *Scand J Clin Lab Invest* 2006, **66**:607-621.
8. Elso CM, Lu X, Culiati CT, Rutledge JC, Cacheiro NL, Generoso WM, Stubbs LJ: **Heightened susceptibility to chronic gastritis, hyperplasia and metaplasia in Kcnq1 mutant mice.** *Hum Mol Genet* 2004, **13**:2813-2821.
9. Judd LM, Andringa A, Rubio CA, Spicer Z, Shull GE, Miller ML: **Gastric achlorhydria in H/K-ATPase-deficient (Atp4a(-/-)) mice causes severe hyperplasia, mucocystic metaplasia and upregulation of growth factors.** *J Gastroenterol Hepatol* 2005, **20**:1266-1278.
10. Friis-Hansen L, Sundler F, Li Y, Gillespie PJ, Saunders TL, Greenson JK, Owyang C, Rehfeld JF, Samuelson LC: **Impaired gastric acid secretion in gastrin-deficient mice.** *Am J Physiol* 1998, **274**:G561-568.
11. Zavros Y, Rieder G, Ferguson A, Samuelson LC, Merchant JL: **Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice.** *Gastroenterology* 2002, **122**:119-133.
12. Friis-Hansen L, Rieneck K, Nilsson HO, Wadstrom T, Rehfeld JF: **Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice.** *Gastroenterology* 2006, **131**:246-258.
13. Kato M, Slack FJ: **microRNAs: small molecules with big roles - C. elegans to human cancer.** *Biol Cell* 2008, **100**:71-81.
14. Fabian MR, Sonenberg N, Filipowicz W: **Regulation of mRNA translation and stability by microRNAs.** *Annu Rev Biochem* 2010, **79**:351-379.
15. Petri A, Lindow M, Kauppinen S: **MicroRNA silencing in primates: towards development of novel therapeutics.** *Cancer Res* 2009, **69**:393-395.
16. Croce CM: **Causes and consequences of microRNA dysregulation in cancer.** *Nat Rev Genet* 2009, **10**:704-714.
17. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: **Accumulation of miR-155 and BIC RNA in human B cell lymphomas.** *Proc Natl Acad Sci USA* 2005, **102**:3627-3632.
18. Ma L, Teruya-Feldstein J, Weinberg RA: **Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.** *Nature* 2007, **449**:682-688.
19. Medina PP, Nolde M, Slack FJ: **OncomiR addition in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.** *Nature* 2010, **467**:86-90.
20. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T: **Dicer1 functions as a haploinsufficient tumor suppressor.** *Genes Dev* 2009, **23**:2700-2704.
21. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T: **Reduced expression of Dicer associated with poor prognosis in lung cancer patients.** *Cancer Sci* 2005, **96**:111-115.
22. Ting AH, Suzuki H, Cope L, Schuebel KE, Lee BH, Toyota M, Imai K, Shinomura Y, Tokino T, Baylin SB: **A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells.** *Cancer Res* 2008, **68**:2570-2575.
23. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, et al: **Dicer, Drosha, and outcomes in patients with ovarian cancer.** *N Engl J Med* 2008, **359**:2641-2650.
24. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B: **Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units.** *Lab Anim* 2002, **36**:20-42.
25. Bjorkholm B, Lundin A, Sillen A, Guillemin K, Salama N, Rubio C, Gordon JL, Falk P, Engstrand L: **Comparison of genetic divergence and fitness between two subclones of Helicobacter pylori.** *Infect Immun* 2001, **69**:7832-7838.
26. Nilsson HO, Ouis IS, Stenram U, Ljungh A, Moran AP, Wadstrom T, Al-Soud WA: **High prevalence of Helicobacter Species detected in laboratory mouse strains by multiplex PCR-denaturing gradient gel electrophoresis and pyrosequencing.** *J Clin Microbiol* 2004, **42**:3781-3788.
27. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al: **Bioconductor: open software development for computational biology and bioinformatics.** *Genome Biol* 2004, **5**:R80.
28. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH: **MicroRNA-145 targets YES and STAT1 in colon cancer cells.** *PLoS One* 2010, **5**:e8836.
29. Jacobsen A, Wen J, Marks DS, Krogh A: **Signatures of RNA binding proteins globally coupled to effective microRNA target sites.** *Genome Res* 2010, **20**:1010-1019.
30. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M: **Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.** *Mol Cell* 2007, **26**:731-743.
31. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al: **Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.** *Mol Cell* 2007, **26**:745-752.
32. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: **A microRNA component of the p53 tumour suppressor network.** *Nature* 2007, **447**:1130-1134.

33. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Mennsen A, Meister G, Hermeking H: **Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.** *Cell Cycle* 2007, **6**:1586-1593.
34. Yamakuchi M, Ferlito M, Lowenstein CJ: **miR-34a repression of SIRT1 regulates apoptosis.** *Proc Natl Acad Sci USA* 2008, **105**:13421-13426.
35. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: **Cancer statistics, 2006.** *CA Cancer J Clin* 2006, **56**:106-130.
36. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: **Cancer statistics, 2007.** *CA Cancer J Clin* 2007, **57**:43-66.
37. Shah MA, Kelsen DP: **Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.** *J Natl Compr Canc Netw* 2010, **8**:437-447.
38. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: **Nature meets nurture: molecular genetics of gastric cancer.** *Hum Genet* 2009, **126**:615-628.
39. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: **p53 alteration in gastric precancerous lesions.** *Am J Pathol* 1994, **144**:511-517.
40. Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelmann JH, Orentreich N, Habel LA: **CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma.** *Carcinogenesis* 2002, **23**:419-424.
41. Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuolo MB, Correa P, Washington MK, El-Rifai W, *et al*: **Regulation of p53 Tumor Suppressor by Helicobacter pylori in Gastric Epithelial Cells.** *Gastroenterology* 2010, **139**:1333-1343.
42. Jiaqing L, Hokita S, Xiangming C, Natsugoe S, Tanabe G, Baba M, Takao S, Aikou T: **Role of cyclin E and p53 expression in progression of early gastric cancer.** *Gastric Cancer* 1998, **1**:160-165.
43. Kouraklis G, Katsoulis IE, Theocharis S, Tsurouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A: **Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?** *Dig Dis Sci* 2009, **54**:1015-1020.
44. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelmann JH, Orentreich N, Sibley RK: **Helicobacter pylori infection and the risk of gastric carcinoma.** *N Engl J Med* 1991, **325**:1127-1131.
45. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ: **Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.** *N Engl J Med* 1991, **325**:1132-1136.
46. Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M: **Downregulation of microRNA-200 in EBV-associated gastric carcinoma.** *Cancer Res* 2010, **70**:4719-4727.
47. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, Liu Z: **Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance.** *J Gastrointest Surg* 2010, **14**:1170-1179.
48. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, *et al*: **MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.** *PLoS Genet* 2010, **6**:e1000879.
49. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M: **MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta.** *Cancer Res* 2010, **70**:2339-2349.
50. Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H: **Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma.** *Mol Cancer* 2010, **9**:16.
51. Kim MS, Oh JE, Kim YR, Park SW, Kang MR, Kim SS, Ahn CH, Yoo NJ, Lee SH: **Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers.** *J Pathol* 2010, **221**:139-146.
52. Zhou H, Guo JM, Lou YR, Zhang XJ, Zhong FD, Jiang Z, Cheng J, Xiao BX: **Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker.** *J Mol Med* 2010, **88**:709-717.
53. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, *et al*: **Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.** *Lancet Oncol* 2010, **11**:136-146.
54. Tsujijura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, *et al*: **Circulating microRNAs in plasma of patients with gastric cancers.** *Br J Cancer* 2010, **102**:1174-1179.
55. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q: **miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A.** *Genes Dev* 2009, **23**:2388-2393.
56. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R: **miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.** *Oncogene* 2009, **28**:1714-1724.
57. Wu W, Lin Z, Zhuang Z, Liang X: **Expression profile of mammalian microRNAs in endometrioid adenocarcinoma.** *Eur J Cancer Prev* 2009, **18**:50-55.
58. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC: **Micromi profiling analysis of differences between the melanoma of young adults and older adults.** *J Transl Med* 2010, **8**:27.
59. Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, Pescatori M, Cardani R, Perbellini R, Isaia E, Sale P, *et al*: **Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia.** *FASEB J* 2009, **23**:3335-3346.
60. Lize M, Pilarski S, Dobbstein M: **E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis.** *Cell Death Differ* 2009, **17**:452-458.
61. Feng M, Yu Q: **miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit.** *Cell Cycle* 2010, **9**:213-214.
62. Welch C, Chen Y, Stallings RL: **MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.** *Oncogene* 2007, **26**:5017-5022.
63. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H: **Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.** *Cell Cycle* 2008, **7**:2591-2600.
64. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH: **p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.** *Cell Death Differ* 2010, **17**:236-245.

doi:10.1186/1476-4598-10-29

Cite this article as: Bou Kheir *et al*: miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. *Molecular Cancer* 2011 **10**:29.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

